Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma, a clinical-stage biotechnology company, announced its participation in the 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the presentation will be available on its website starting at 1:00 a.m. ET on September 13.

Management will discuss advancements in antiviral programs targeting SARS-CoV-2 and influenza. Notable developments include the anticipated initiation of a Phase 1 trial for CC-42344 for influenza A treatments, with IND-enabling studies expected in early 2022.

Cocrystal Pharma (Nasdaq: COCP) reported no revenues for Q2 2021, down from $554,000 in Q2 2020, as Merck has assumed all development expenses for their influenza A/B program. The company's R&D expenses rose to $2.7 million, reflecting investments in COVID-19 and influenza programs. Cocrystal has $67 million in cash, sufficient to fund operations beyond 2024. Upcoming milestones include the initiation of Phase 1 clinical trials for CC-42344 and IND-enabling studies for COVID-19 antiviral compounds in 2022, after encouraging preclinical results.

Cocrystal Pharma (Nasdaq: COCP) announced that its SARS-CoV-2 protease inhibitor, CDI-45205, along with its analogs, showed strong in vitro efficacy against the Delta and Gamma variants of SARS-CoV-2. Previously, this compound demonstrated broad-spectrum activity against other variants, indicating potential as a treatment for COVID-19. Cocrystal plans to scale up synthesis for IND-enabling studies to bring CDI-45205 into clinical trials. The company's continued development of oral protease inhibitors aims to create effective coronavirus antivirals.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has been added to the Russell Microcap® Index as of June 28, 2021. This addition marks a significant milestone, enhancing the company’s visibility in the investment community. The company focuses on developing novel antiviral therapeutics targeting various viruses, including influenza and coronaviruses. Cocrystal plans to initiate a Phase 1 trial for influenza A in Q3 2021. Membership in the index is based on market capitalization and style attributes and remains valid for one year.

Cocrystal Pharma (Nasdaq: COCP) has completed IND-enabling studies for its broad-spectrum PB2 inhibitor, CC-42344, aimed at treating seasonal and pandemic influenza A. The company plans to initiate a Phase 1 clinical trial in Australia in Q3 2021. A 14-day GLP toxicology study has confirmed the drug's safety prior to human trials. This antiviral has the potential to overcome challenges posed by existing treatments that are vulnerable to resistance. The World Health Organization estimates that seasonal influenza affects 1 billion people annually, highlighting the need for effective antiviral solutions.

Cocrystal Pharma (Nasdaq: COCP) announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205, shows potent activity against SARS-CoV-2 and two variants, B.1.1.7 and B.1.351. In vitro studies revealed CDI-45205 had an EC50 of 1.9 uM against the UK variant and 2.5 uM against the South African variant, outperforming comparator drugs like remdesivir. Cocrystal aims to further test CDI-45205 against emerging variants, reinforcing its potential as a COVID-19 treatment.

Cocrystal Pharma (Nasdaq: COCP) announced that management's participation in the Noble Capital Markets C-Suite Interview Series is now available online. The discussion covered their antiviral drug development programs targeting various viruses, with upcoming milestones including a proof-of-concept study for norovirus and a Phase 1 study for influenza A planned for Q3 2021. Interim co-CEO James Martin stated that the company has sufficient capital to fund operations through 2024, without the expectation of raising additional capital in 2021.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announced the passing of its Chairman and CEO, Gary Wilcox, on May 26, 2021. He was 74 years old. The Board appointed Sam Lee, Ph.D., and James Martin as interim co-CEOs while searching for a successor. Roger Kornberg, Ph.D., co-founder, now serves as Chairman of the Board. New board member Richard C. Pfenniger, Jr. is expected to provide governance expertise. The company remains focused on advancing antiviral treatments, reflecting on Wilcox's significant contributions to biotechnology.

Cocrystal Pharma, Inc. (Nasdaq: COCP) reported Q1 2021 results, highlighting no revenues due to a collaboration transition with Merck. The company has $33.3 million in cash and plans to advance antiviral programs targeting COVID-19, influenza, and norovirus. Key updates include progress on the SARS-CoV-2 protease inhibitor CDI-45205 and the initiation of a Phase 1 study for influenza drug CC-42344. Cocrystal anticipates significant market opportunities with its antiviral pipeline, reinforced by a recent $36.4 million capital raise.